May 8th 2024
During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Acalabrutinib May Be A Safer Alternative to Ibrutinib in CLL
May 7th 2020In an interview with Targeted Oncology, Lori A. Leslie, MD, discussed the importance of analyzing treatment outcomes in real-world patients with chronic lymphocytic leukemia compared with only reviewing data from clinical trials that do not represent all patients seen in the community setting.
Read More
Longest Follow-Up Maintains Ibrutinib Benefit in CLL/SLL Across Treatment Settings
April 13th 2020The longest follow-up for ibrutinib monotherapy to date maintained the benefit of the Bruton’s tyrosine kinase inhibitor for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma across settings.<br />
Read More
Prognostic Tool Predicts Length of Watch and Wait Period in CLL
April 10th 2020The appropriate gap between diagnosis of chronic lymphocytic leukemia and treatment is now clearer as a new prognostic tool, IPS-E, that can predict the length of “watch and wait” has been introduced, according to a press release from the American Society of Hematology.
Read More
Early FCR Lacks Evidence to Change Standard Watch & Wait in Stage Binet A High-Risk CLL
April 2nd 2020Although fludarabine, cyclophosphamide, and rituximab may be efficient in inducing remission for the treatment of patients with Binet A high-risk chronic lymphocytic leukemia, recent data published in Leukemia suggest there is no evidence that this would be better than the current standard of care, which is the “watch and wait” approach.
Read More
Acalabrutinib Appears Tolerable in Chronic Lymphocytic Leukemia
April 2nd 2020Jeff P. Sharman, MD, discusses the secondary end points from the <u><strong><a href="https://www.targetedonc.com/conference/ash-2019/patients-with-cll-treated-on-the-elevatetn-trial-experience-improved-pfs-with-acalabrutinib">phase III ELEVATE-TN trial</a></strong></u>, which evaluated the role of acalabrutinib, either as a single agent or in combination with obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.
Watch